Regeneron and its close partner Sanofi have cleared the final mid-stage hurdle for dupilumab in asthma patients, with several doses hitting the trial endpoint both for a subset of patients as well ...

The QUEST pivotal Phase 3 trial enrolled 1,902 patients including 1,795 adults and 107 adolescents across 413 study sites worldwide. The four study groups included patients treated with 200 mg ...

TARRYTOWN, N.Y. and PARIS, May 20, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented late-breaking data from the NOTUS Phase 3 trial evaluating the ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi (SNY) announced Tuesday that a pivotal Phase 3 trial of Dupixent (dupilumab) met its primary and all key secondary endpoints in ...

Dupilumab was found to significantly reduce exacerbations in adults with uncontrolled chronic obstructive pulmonary disease (COPD) and evidence of type 2 inflammation, according to findings from ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi (SNY) announced Monday positive results from the second Dupixent (dupilumab) Phase 3 Eosinophilic Esophagitis trial that showed ...

Regeneron has advanced dupilumab, regarded by many as the company's next big innovation, into a Phase III asthma study, rolling toward an FDA submission behind its lead eczema program.

Regeneron Pharmaceuticals and Sanofi are collaborating on a Phase 4 clinical study titled ‘A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Dupilumab on Airway ...

To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation.

Dupilumab has also shown strong hints of safety and effectiveness in two early-stage trials that involved 67 patients with atopic dermatitis. Larger studies are slated to begin later this year.

Send comments and news tips to [email protected]. Cite this: Edited by Vinod Rane. Dupilumab Safe, Effective Over 5 Years in Moderate to Severe Atopic Dermatitis - Medscape - July 10, 2024.